The Newsroom

Investigations  /  06.10.2019

Shareholder Investigation of Corbus Pharmaceuticals Holdings

You Have Legal Options

Corbus Pharmaceutical Holdings, Inc. (CRBP) Accused of Faking Clinical Results for Lenabasum

According to the complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and February 28, 2019, since 2016, Corbus Pharmaceutical Holdings, Inc. (CRBP) falsely assured investors with reports of positive clinical data in its studies for Lenabasum. Then, on February 28, 2019, a SeekingAlpha article was published denouncing the company’s results by stating that Lenabasum’s “Phase 2 trial in SSc was a massive failure.” When the truth about Lenabasum was revealed, Corbus’ stock fell almost 16% on February 28, 2019. The stock still trades below its class period high.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns